Starpharma Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Starpharma Holdings şirketinin toplam hissedar öz sermayesi A$28.1M ve toplam borcu A$775.0K olup, bu da borç-öz sermaye oranını 2.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$36.8M ve A$8.7M dir.

Anahtar bilgiler

2.8%

Borç/özkaynak oranı

AU$775.00k

Borç

Faiz karşılama oranı	n/a
Nakit	AU$23.36m
Eşitlik	AU$28.12m
Toplam yükümlülükler	AU$8.70m
Toplam varlıklar	AU$36.81m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SPL 'nin kısa vadeli varlıkları ( A$32.9M ) kısa vadeli yükümlülüklerini ( A$6.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: SPL şirketinin kısa vadeli varlıkları ( A$32.9M ) uzun vadeli yükümlülüklerini ( A$2.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SPL şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: SPL şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 2.8% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SPL şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: SPL serbest nakit akışı her yıl % 1.9 2.3 yıl yetecek nakit akışına sahip olacaktır.

Starpharma Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

Starpharma Releases New Data About SPL7013

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Starpharma Signs DEP ADC Research Agreement with MSD

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.79

New 90-day high: AU$1.66

New 90-day low: AU$1.27

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Announces SPL7013 Shows Potent Antiviral Activity in RSV Expanding Use for Nasal Spray

Starpharma Holdings Limited announced that it has received AUD 45 million in funding

Starpharma Holdings Limited announced that it expects to receive AUD 45 million in funding

Starpharma Holdings Limited Announces That Australia Therapeutic Goods Administration Approves Expansion of the Marketing Authorisation for Vivagel® Bv

New 90-day high - AU$1.73

Earnings released

New 90-day high - AU$1.28

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin